D. Lansing Taylor

D. Lansing Taylor serves as Director of the University of Pittsburgh Drug Discovery Institute (UPDDI) and holds the Allegheny Foundation Professorship in Computational and Systems Biology. His leadership integrates academic research with commercial drug development through the UPDDI's technical platforms spanning discovery chemistry, computational biology, and preclinical assessment.

Dr. Taylor's educational foundation includes:

• BS in Zoology from University of Maryland (1968)
• PhD in Cell Biology from SUNY Albany (1973)
• Postdoctoral Fellowship in Biophysics at Woods Hole Marine Biology Laboratory (1974)

His research pioneers the coupling of Quantitative Systems Pharmacology (QSP) with Microphysiology Systems (MPS) to model disease mechanisms and drug responses. Current work focuses on liver diseases (NAFLD/T2D), cancer metastasis, and neurodegenerative disorders using fluorescent biosensors and spatial analytics. This approach bridges patient-derived cell models with computational prediction of therapeutic outcomes through platforms like BioSystics.

Analysis of recent publications reveals three dominant trends: (1) Integration of multi-organ MPS for ADME-Tox and disease modeling, (2) Spatial analytics for cancer recurrence prediction using tissue microdomain networks, and (3) Development of predictive safety assessment platforms combining primary hepatocytes with machine learning. These efforts consistently advance the paradigm of human biomimetic systems for precision medicine.

No specific scientific awards or fellowships are detailed in the source text, though his endowed professorship and institute directorship represent significant institutional recognition.

Dr. Taylor has mentored numerous researchers through UPDDI's academic-industry collaborations and directed major grant initiatives including the NSF-funded Center for Light Microscope Imaging. His entrepreneurial leadership includes founding three successful biotech companies: Cellomics (acquired by Thermo Fisher), Cellumen (acquired by Cyprotex), and Cernostics (acquired by Castle Biosciences).

The UPDDI operates as a comprehensive ecosystem with core facilities in computational chemistry, zebrafish modeling, and preclinical efficacy testing. His current lab work focuses on developing patient digital twin technology through PredxBio and BioSystics, advancing spatial analytics for clinical diagnostics while directing UPDDI's large-scale programs on liver MPS and cancer microenvironments.